Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00484
|
|||||
| Drug Name |
Pimozide
|
|||||
| Synonyms |
1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one; ASTA Medica Brand of Pimozide; Antalon; Janssen Brand of Pimozide;Orap forte; McN-JR 6238; McN-JR-6238; Neoperidole; Opiran; Orap; Orap (TN); P 1793; Pharmascience Brand of Pimozide; Pimozida; Pimozida [INN-Spanish]; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; Pimozidum; Pimozidum [INN-Latin]; Primozida; Primozida [INN-Spanish]; R 6238; R-6238
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11: 6A20] | Approved | [1] | |||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C28H29F2N3O
|
|||||
| Canonical SMILES |
C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
|
|||||
| InChI |
InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
|
|||||
| InChIKey |
YVUQSNJEYSNKRX-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 2062-78-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 461.5 | Topological Polar Surface Area | 35.6 | ||
| Heavy Atom Count | 34 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
6.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321421
, 11111615
, 11112507
, 11113804
, 11335561
, 11360800
, 11363339
, 11365901
, 11368463
, 11372540
, 11373859
, 11376625
, 11447004
, 11461772
, 11466336
, 11467456
, 11484947
, 11486231
, 11488842
, 11491266
, 11492235
, 11494259
, 12013418
, 14882544
, 17405504
, 24277923
, 26612186
, 26680826
, 26747138
, 26747139
, 26751488
, 26751978
, 26751979
, 29284219
, 46507096
, 47275121
, 47275122
, 47423792
, 47572947
, 47720184
, 47720185
, 563187
, 6706026
, 7847626
, 7980325
, 8137196
, 8149730
, 8162258
, 855710
, 9769
|
|||||
| ChEBI ID |
ChEBI:8212
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Pimozide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.